(Reuters) -Neutrogena-owner Kenvue's third-quarter sales fell short of expectations on Thursday, marking the fifth ...

Kenvue reported third-quarter sales slightly below Wall Street expectations on Thursday, hurt by weak sales of its skin ...

Kenvue Inc., the owner of Tylenol and Neutrogena, reported sales that trailed estimates after its skin health and beauty ...

Net income: US$383.0m (down 13% from 3Q 2023). Profit margin: 9.8% (down from 11% in 3Q 2023). EPS: US$0.20 (down from ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Hello, and welcome to the Kenvue Third Quarter 2024 Earnings ...

Headlines,Institutional investors increase their stakes in Kenvue Inc.,XML Financial LLC acquires significant position in ...

Kenvue owns a strong portfolio of household brands like Tylenol, Benadryl and Band-Aid. Read why I continue to rate KVUE ...

Kenvue announced financial results for the fiscal third quarter which ended September 29, 2024. Net sales in Q3 reached ...

Kenvue reports Q3 sales of $3.89 billion, slightly missing estimates. Strong growth in Essential Health offsets declines in ...

Kenvue reported third-quarter sales marginally below Wall Street estimates on Thursday, hurt by weakness in its skin health and beauty unit housing the Neutrogena and Aveeno brands, amid pressure from ...

The Neutrogena owner has named former Hydrafacial and Coty exec Stanleick as President, Skin Health & Beauty for North ...

Jefferies has recently initiated Kenvue Inc (KVUE) stock to Buy rating, as announced on September 24, 2024, according to Finviz. Earlier, on September 24, 2024, RBC Capital Mkts had reduced the stock ...